during the fast evolving area of oncology analysis, correct and successful mutation screening is critical for producing focused therapies. The KRAS products and services System plays a pivotal role During this landscape by featuring thorough methods for KRAS mutation profiling and Assessment. KRAS mutations, found in around 95% of RAS-connected onc